Europe is nearing the end of its summer holiday season, and investors and biotech companies are idling, reviewing events from the past year and fine-tuning plans for the coming months.

The first half of 2001 saw some interesting deals. There was Bayer’s $1.5 billion alliance with Curagen to discover new metabolic targets, and Merck’s acquisition of the bioinformatics company Rosetta, which cost $600 million at a 100 percent premium that reflected the enormous strategic value of bio  IT.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.